Ascletis Launches Phase III Trials for Once-Daily Oral Weight Management Drug ASC30

Ascletis Initiates Global Phase III Trials for ASC30

In an exciting advancement in obesity treatment, Ascletis Pharma Inc. has officially initiated a global Phase III clinical program for its innovative oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, ASC30. The first participant has been dosed, marking a significant milestone in the company's journey to deliver a promising solution for chronic weight management. This therapeutic is designed to help individuals with obesity or being overweight, aiming to transform how weight management is approached across the globe.

Study Overview

The global Phase III program includes two pivotal trials, AURORA-1 and AURORA-2, that will evaluate the long-term effectiveness, safety, and tolerability of ASC30 in around 4,600 participants from diverse clinical sites in the United States, Europe, and Canada. The trials will span 72 weeks, and participants will be randomized to receive one of three maintenance doses of ASC30 (20 mg, 40 mg, or 60 mg) or a placebo. AURORA-1 specifically targets participants with obesity or overweight who do not have type 2 diabetes, while AURORA-2 focuses on those with type 2 diabetes, examining the weight loss benefits of ASC30 across different demographics.

Unmet Needs in Obesity Management

Dr. Jinzi Jason Wu, founder and CEO of Ascletis, emphasized the pressing need for effective oral therapies for obesity. ‘Obesity is a multifaceted chronic condition that often coincides with over 200 comorbidities and significantly burdens global public health systems. Injectable therapies have made substantial differences, yet many patients seek accessible and convenient oral solutions that are effective and have manageable side effects.’ The rollout of ASC30 aims to fill this significant gap, making treatment more approachable for the millions living with weight-related challenges.

Anticipated Outcomes

The topline data from these critical trials are projected to be available by the third quarter of 2028, with the company planning to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of that year. European Medicines Agency (EMA) marketing authorization is also anticipated in early 2029, positioning ASC30 to potentially become the second oral GLP-1 receptor agonist available in the U.S. and Europe, pending successful trials.

About ASC30

ASC30 stands out as a proprietary treatment developed entirely in-house by Ascletis. Its oral formulation represents a shift in treatment paradigms for obesity management, with a focus on providing a convenient daily option for patients. The drug has already exhibited a compelling profile in previous Phase II trials, showcasing favorable gastrointestinal tolerability and a solid weight loss effect.

Ascletis’ Commitment to Innovation

Ascletis not only focuses on ASC30 but is also expanding its portfolio with additional oral small molecule candidates targeting obesity, including promising combinations of GLP-1 and other peptide therapies. These new products have the potential to offer even more innovative solutions for managing obesity and related metabolic diseases, crucial in today's health landscape.

In summary, as Ascletis embarks on this global Phase III clinical program, the hope is that ASC30 will set a new standard in oral therapies for chronic weight management, granting patients an effective, convenient, and accessible option to address their health goals. The advancements in this area of medicinal treatment stand to reshape the future of obesity management profoundly, making strides towards a healthier global population.

For further updates and insights regarding Ascletis and its developmental programs, stay connected with their official communications.